List of Excipients in Branded Drug GRISEOFULVIN ORAL SUSPENSION

Generic Drugs Containing GRISEOFULVIN ORAL SUSPENSION

Company	Ingredient	NDC	Excipient
TriRx Huntsville Pharmaceutical Services LLC	griseofulvin oral suspension	80432-056	ALCOHOL
TriRx Huntsville Pharmaceutical Services LLC	griseofulvin oral suspension	80432-056	DIMETHICONE
TriRx Huntsville Pharmaceutical Services LLC	griseofulvin oral suspension	80432-056	DOCUSATE SODIUM

What are the Most Frequently-Used Excipients in GRISEOFULVIN ORAL SUSPENSION?

# Of NDCs	Excipient
1	ALCOHOL
1	DIMETHICONE
1	DOCUSATE SODIUM

Last updated: August 18, 2026

ecutive summary: Griseofulvin oral suspension is a low-cost, off-patent antifungal product with commercial potential in pediatric dosing, improved palatability, sugar-free formulations, and global-access markets. The main technical problem is poor aqueous solubility and variable absorption. A competitive product should combine controlled particle size, robust suspension stability, acceptable taste, dose-measuring accuracy, and food-independent or more predictable exposure. Patent value is likely to reside in formulation, manufacturing, packaging, or device claims rather than in the griseofulvin molecule.

Griseofulvin Oral Suspension Excipient Strategy and Commercial Opportunities

What excipient strategy is required for griseofulvin oral suspension?

Griseofulvin is practically insoluble in water. Oral performance depends on particle size, dispersion, wetting, gastrointestinal dissolution, and administration with food. FDA labeling for microsize griseofulvin products states that absorption improves when the drug is taken with a fatty meal.[1]

A commercial suspension should be designed around five objectives:

1. Keep griseofulvin uniformly dispersed through the dosing interval.
2. Prevent hard caking and irreversible sedimentation.
3. Improve wetting and dissolution without creating excessive foaming.
4. Mask the drug’s bitter or unpleasant taste.
5. Maintain microbial quality throughout multi-dose use.

The formulation should generally use a structured vehicle rather than rely only on high viscosity. Excessive viscosity can improve physical stability but reduce pourability, dose recovery, syringeability, and pediatric acceptability.

Which excipients are most relevant to griseofulvin suspension development?

Wetting and dispersion agents

Griseofulvin particles can float, agglomerate, or resist wetting. A low concentration of a surfactant may improve dispersion and dissolution. Candidate classes include:

• Polysorbates
• Polyoxyl castor oils
• Sodium lauryl sulfate, where justified by tolerability
• Lecithin or other phospholipid-based wetting systems

Polysorbate 80 is a common early-screening candidate for hydrophobic active ingredients, but its concentration must be controlled because excessive surfactant can cause foaming, taste problems, or preservative interactions. Surfactant selection should be tested against particle-size distribution, dissolution, adsorption to packaging, and degradation during storage.

Suspending and rheology-control agents

Suitable suspending systems may include:

• Xanthan gum
• Sodium carboxymethylcellulose
• Hydroxypropyl cellulose
• Microcrystalline cellulose and carboxymethylcellulose combinations
• Carbomers
• Pregelatinized starch or other polysaccharide systems

A useful profile is pseudoplastic or shear-thinning behavior. The product should become less viscous during shaking and pouring, then recover enough structure at rest to limit sedimentation.

The formulation should be evaluated for:

• Sedimentation volume
• Redispersibility after extended storage
• Pourability
• Dose uniformity at the beginning, middle, and end of bottle use
• Syringe withdrawal force
• Viscosity across temperature conditions
• Compatibility with high-density polyethylene and polypropylene packaging

Sweeteners and taste-masking agents

Griseofulvin suspension is likely to require an active taste-masking strategy. Options include:

• Sucrose
• Sorbitol
• Xylitol
• Sucralose
• Acesulfame potassium
• Aspartame, subject to phenylalanine labeling requirements

A high-sucrose product may provide the best taste profile but creates a commercial disadvantage for patients with diabetes, dental-risk concerns, or dietary restrictions. A sugar-free formulation using sorbitol, glycerin, and high-intensity sweeteners could expand the addressable market, although polyol content may cause gastrointestinal effects in sensitive children.

Flavor selection should be tested after the drug is swallowed, not only on the tongue. Fruit flavors can mask initial bitterness but may leave a lingering aftertaste. Flavor systems also need stability testing against pH, preservatives, light, and oxidation.

Preservatives

A multi-dose aqueous suspension usually requires microbial protection unless the package and formulation provide an alternative validated control strategy. Candidate preservatives include:

• Sodium benzoate
• Potassium sorbate
• Methylparaben and propylparaben
• Benzalkonium chloride in limited, product-specific circumstances

Preservative efficacy must be established in the final formulation, not inferred from the concentration of the preservative alone. Surfactants, polymers, flavor oils, and container surfaces can reduce the free concentration of a preservative.

USP <51> antimicrobial effectiveness testing and USP <61>/<62> microbial testing are relevant to development and release.[2]

Buffers and pH control

A mildly acidic formulation may improve preservative performance and flavor stability, but pH must be selected based on griseofulvin chemical stability, excipient compatibility, and oral tolerability. Candidate buffers include citrate and phosphate systems.

pH screening should include:

• Assay and degradation products
• Preservative effectiveness
• Viscosity
• Flavor stability
• Container compatibility
• Dissolution after dilution in gastrointestinal media

What formulation attributes create the strongest commercial differentiation?

The strongest opportunities are likely to come from measurable patient or pharmacy benefits rather than from routine excipient substitution.

Product concept	Commercial benefit	Main development risk
Sugar-free suspension	Expands use among patients avoiding sucrose	Taste and polyol tolerability
Improved taste formulation	Better pediatric adherence	Flavor masking may not control lingering bitterness
Low-settling suspension	More reliable dosing	Increased viscosity and poor pourability
Oral-syringe-compatible product	Better pediatric dose accuracy	Packaging and withdrawal-force validation
Smaller bottle or unit-dose package	Reduced waste and improved portability	Higher packaging cost
Preservative-reduced or preservative-free product	Differentiation for sensitive patients	Microbial-control burden
Higher-strength suspension	Lower dose volume	Dose-measurement and uniformity risk
Food-effect-reduced formulation	More predictable exposure	May require significant formulation technology
Extemporaneous reconstitution product	Longer shelf-life before use	Pharmacy handling and reconstitution errors

The most defensible near-term proposition is a well-tolerated pediatric suspension with validated dose uniformity and a calibrated oral syringe. A formulation that materially reduces the effect of food on exposure would have greater technical value but would require comparative pharmacokinetic evidence.

What particle-size strategy is appropriate for griseofulvin suspension?

Griseofulvin products have historically used microsize and ultramicrosize presentations. Particle size affects surface area, dissolution rate, sedimentation behavior, and dose uniformity. Reducing particle size can improve dissolution, but very fine particles may agglomerate, become difficult to wet, or generate a suspension with poor flow.

Development should control:

• D10, D50, and D90 particle-size values
• Span and distribution tail
• Crystal morphology and polymorphic form
• Surface energy and agglomeration
• Milling-induced degradation
• Dissolution in biorelevant media
• Uniformity after storage and shaking

A particle-size specification should be linked to clinical or in vitro performance. A narrow specification without evidence of performance relevance may add manufacturing cost without creating meaningful protection.

Wet milling, micronization, high-shear dispersion, and spray-dried dispersion approaches can be assessed. For a conventional suspension, wetting and controlled flocculation may offer a lower-cost path than a complex amorphous system. Any process that changes solid-state form requires solid-state characterization and stability monitoring.

What FDA regulatory status applies to griseofulvin oral suspension?

Griseofulvin is an established oral antifungal drug. FDA labeling covers microsize and ultramicrosize products, with use in dermatophyte infections such as tinea corporis, tinea capitis, tinea pedis, and related conditions.[1]

A new U.S. oral suspension would generally require an abbreviated new drug application if it can demonstrate pharmaceutical equivalence and bioequivalence to a suitable reference product. If no appropriate reference suspension is available, the sponsor may face a more complex regulatory pathway, including additional clinical pharmacology or clinical evidence.

Key regulatory issues include:

• Whether the proposed product is a suspension or another dosage-form category
• Reference-listed drug availability
• Strength and concentration
• Particle-size comparability
• In vitro dissolution and dose uniformity
• Food-effect evaluation
• Preservative effectiveness
• Container-closure performance
• Labeling for shaking and measuring the dose
• Pediatric-use data and dosing instructions

The FDA Inactive Ingredient Database can support excipient precedent assessment, but precedent does not replace formulation-specific safety and quality justification.[3]

What is the Orange Book and patent status of griseofulvin suspension?

The foundational griseofulvin molecule and early oral formulations have long passed their original patent terms. Current U.S. exclusivity risk is therefore more likely to arise from a later formulation patent, manufacturing patent, trademark, or regulatory designation than from the active ingredient.

Orange Book status must be assessed by product and dosage form. A patent listed against a tablet or capsule does not automatically protect an oral suspension. Relevant review items include:

Exclusivity or IP category	Relevance to griseofulvin suspension
Active-ingredient patent	Low likelihood of current relevance
Composition-of-matter patent	Expired for an established molecule
Suspension composition patent	Potentially relevant if still enforceable
Particle-size or solid-state patent	Relevant where claims cover a defined product
Manufacturing-process patent	Could delay a specific production route
Device or dosing-system patent	Relevant to oral syringe or metered delivery
Method-of-use patent	Potentially relevant for a new disease, regimen, or population
Trademark rights	Commercially relevant but not a barrier to generic manufacture
FDA exclusivity	Must be checked against the specific reference product

The most valuable patent strategy would claim a defined combination of particle-size distribution, excipient concentrations, redispersibility, dissolution performance, and pharmacokinetic behavior. Broad claims covering ordinary suspending agents are vulnerable to prior-art and obviousness challenges.

When does griseofulvin lose exclusivity, and what generic entry risks exist?

For the active ingredient, conventional patent exclusivity has already expired. Generic entry risk is therefore high for standard oral presentations. A new suspension would face competition from:

• Existing generic tablets or capsules
• Other oral suspensions
• Compounded formulations
• Imported products in price-sensitive markets
• Alternative antifungals such as terbinafine and itraconazole

The commercial risk is greatest where prescribers can substitute tablets for older children or adults. The suspension has a stronger position in young children, patients with swallowing difficulties, and settings requiring weight-based dosing.

A Paragraph IV challenge would matter only if a later-listed, unexpired patent covers the reference suspension or a relevant formulation. Because patent protection is product-specific, the existence of an Orange Book patent for another griseofulvin dosage form would not by itself block suspension entry.[4]

Which companies are competing in griseofulvin oral suspension?

The competitive field has historically included branded and generic suppliers of microsize griseofulvin oral suspension, as well as manufacturers of Gris-PEG and other oral forms. Market participation can change because of discontinuations, supply interruptions, and limited commercial value.

The relevant competitive dimensions are:

• Current FDA-approved supply
• Wholesale acquisition cost
• Generic availability
• Pediatric concentration
• Sugar content
• Bottle size
• Oral syringe inclusion
• Stability after opening
• Pharmacy substitution status
• Hospital and public-health procurement access

A sponsor should not rely on historical brand recognition. Current product availability and wholesaler data determine whether a market gap exists.

What licensing deals and manufacturing barriers affect the opportunity?

There is no established commercial logic for licensing the griseofulvin molecule itself. Licensing value would more likely attach to:

• A proprietary micronization or wet-milling process
• A taste-masking platform
• A long-stability preservative system
• A sugar-free pediatric vehicle
• A validated oral-syringe package
• Regional manufacturing or distribution rights
• An approved product with established procurement contracts

Manufacturing barriers are moderate. Griseofulvin is not a biologic and does not require cold-chain distribution under ordinary conditions. The main barriers are process consistency, particle-size control, microbial quality, suspension uniformity, and acceptable taste.

A contract manufacturer must demonstrate control of high-shear processing, powder dispersion, filling accuracy, cleaning validation, and container-closure compatibility. A poorly controlled suspension can produce clinically meaningful dose variability even when the assay result passes.

How does griseofulvin suspension compare with competing antifungal formulations?

Product type	Main advantage	Main limitation
Griseofulvin oral suspension	Established pediatric use and weight-based dosing	Poor solubility, food-dependent absorption, long treatment courses
Griseofulvin tablet	Lower packaging complexity and established supply	Difficult for young children to swallow
Terbinafine granules or tablets	Shorter treatment in some dermatophyte infections	Different age, indication, and safety considerations
Itraconazole oral solution	Liquid dosage form and broad antifungal activity	Taste, drug interactions, and pharmacokinetic complexity
Compounded suspension	Can meet local dosing needs	Variable stability, quality, and availability

Griseofulvin remains commercially relevant where pediatric administration and established clinical familiarity outweigh the inconvenience of prolonged treatment.

What is the revenue exposure and commercial launch outlook?

Revenue potential is likely to be niche rather than blockbuster. The opportunity improves if the product secures:

• Pediatric dermatology and primary-care adoption
• Hospital formulary placement
• Public-health or school-based treatment contracts
• Reliable generic supply
• A lower-cost sugar-free presentation
• Distribution in markets where liquid antifungal supply is limited

A generic suspension can win on availability, dose accuracy, and patient acceptability. Premium pricing requires evidence of a meaningful benefit, such as improved adherence, reduced dosing errors, longer in-use stability, or more predictable exposure.

Key Takeaways

• Griseofulvin oral suspension is an off-patent, formulation-led opportunity.
• The core technical challenge is poor solubility combined with suspension uniformity and food-sensitive absorption.
• The highest-value excipient work concerns wetting, controlled rheology, taste masking, preservative performance, and sugar-free design.
• A pediatric oral syringe and robust redispersibility may provide more practical value than a marginal change in excipient composition.
• Current patent risk is likely to center on later formulation, process, packaging, or method-of-use claims.
• Commercial returns are likely to be moderate unless the product fills a documented supply gap or offers a validated adherence or dosing advantage.

FAQs about griseofulvin oral suspension development

Can griseofulvin oral suspension be formulated without sucrose?

Yes. Sorbitol, glycerin, xylitol, and high-intensity sweeteners can replace sucrose, but the sponsor must manage bitterness, osmolarity, gastrointestinal tolerability, and preservative performance.

Does griseofulvin oral suspension require a food-effect study?

The need depends on the regulatory pathway and reference product. Because food, particularly dietary fat, can improve griseofulvin absorption, food-effect evidence is commercially and clinically relevant.[1]

Is micronized griseofulvin automatically bioequivalent to ultramicronized griseofulvin?

No. Particle-size designation alone does not establish bioequivalence. Dissolution, exposure, dose, formulation composition, and the applicable FDA product standard control the assessment.

What packaging is best for pediatric griseofulvin suspension?

A light-protective, multi-dose bottle with a calibrated oral syringe is generally commercially attractive. The final package requires dose-delivery, extractables and leachables, in-use stability, and child-safety evaluation.

Can an excipient combination create patent protection for griseofulvin suspension?

Potentially, but protection depends on novelty, nonobviousness, enablement, and claim scope. Routine combinations of known sweeteners, suspending agents, and preservatives are less defensible than compositions tied to demonstrated performance.

References

1. U.S. Food and Drug Administration. (n.d.). Griseofulvin microsize oral suspension prescribing information. DailyMed.
2. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: General chapters <51>, <61>, and <62>.
3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.